`
`
`
`
`(212) 373-3000
`
`(212) 757-3990
`
`ngroombridge@paulweiss.com
`
`August 23, 2022
`
`By ECF
`
`The Honorable Mary Kay Vyskocil
`Daniel Patrick Moynihan U.S. Courthouse
`500 Pearl Street
`New York, NY 10007-1312
`
`Re:
`
`Acuitas Therapeutics Inc. v. Genevant Sciences GmbH
`and Arbutus Biopharma Corp., Case No. 1:22-cv-02229-MKV
`
`Dear Judge Vyskocil:
`
`I write on behalf of Plaintiff Acuitas Therapeutics Inc. (“Acuitas”) in response to the
`Court’s August 16, 2022 Order [D.I. 37] regarding Acuitas’s intent to amend its complaint [D.I. 1]
`in response to the arguments raised in the proposed motion to dismiss by Genevant Sciences GmbH
`and Arbutus Biopharma Corp. (collectively, “Defendants”) [D.I. 31, 34].
`
`Acuitas will amend its complaint by September 6, 2022. Although Defendants’ proposed
`motion to dismiss for lack of subject matter jurisdiction asserts the absence of an actual controversy
`and of injury-in-fact, rather than attacking the sufficiency of the pleadings, and although the Court
`“may review evidence extrinsic to the pleadings” when deciding such a motion, see, e.g., 3M Co.
`v. Avery Dennison Corp., 673 F.3d 1372, 1378 (Fed. Cir. 2012), to streamline the process and in
`response to Your Honor’s Order, Acuitas will amend.
`
`We thank the Court for the opportunity to do so.
`
`
`
`
`
`
`
`Case 1:22-cv-02229-MKV Document 39 Filed 08/23/22 Page 2 of 2
`
`
`
`Respectfully submitted,
`
`
`/s/ Nicholas Groombridge
`Nicholas Groombridge
`Eric Alan Stone
`Josephine Young
`Allison C. Penfield
`Chih-Wei Wu
`PAUL, WEISS, RIFKIND, WHARTON & GARRISON
`LLP
`1285 Avenue of the Americas
`New York, NY 10019
`(212) 373-2000
`
`Saurabh Gupta
`PAUL, WEISS, RIFKIND, WHARTON & GARRISON
`LLP
`2001 K Street, NW
`Washington, DC 20006
`(202) 223-7300
`
`
`Attorneys for Plaintiff Acuitas Therapeutics Inc.
`
`
`
`
`
`
`
`
`
`
`